Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...

Burroughs, F.Med.Sci.; Amar P. Dhillon, M.D. The liver biopsy specimen represents valuable material for the assessment of fibrosis and cirrhosis. Despite limitations related to sampling and ...

Chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis (also called idiopathic pulmonary fibrosis, or IPF) are both serious lifelong diseases that make it hard for you to breathe.

Introduction: Idiopathic pulmonary fibrosis (IPF) is a severe chronic respiratory disease characterized by treatment challenges and poor prognosis. Identifying relevant biomarkers for effective ...

Additionally, artificial intelligence can predict driver mutations by analyzing biopsy images, potentially eliminating the need for molecular testing. While acknowledging artificial intelligence's ...

Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase ...